← All diseases
Liver, kidneys and digestion
Primary biliary cholangitis
Do you want to receive a message when there is new research about Primary Biliary Cholangitis? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, above each publication you'll find one sentence explaining what was studied — and you'll receive a message as soon as there is new research about Primary Biliary Cholangitis. View what Premium costs.
Publications and studies (1840)
- External validation of EncephalApp Stroop test to screen minimal hepatic encephalopathy patients with nonalcoholic cirrhosis. (2024/12/27) ♡
- A new diagnosis of primary biliary cholangitis in pregnancy treated with a combination of ursodeoxycholic acid and bezafibrate. (2024/12/25) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Hepatic angiosarcoma in a patient treated with obeticholic acid for primary biliary cholangitis. (2024/12/24) ♡
- Elafibranor (Iqirvo) for primary biliary cholangitis. (2024/12/23) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. AI in Hepatology: Revolutionizing the Diagnosis and Management of Liver Disease. (2024/12/22) ♡
- Probing the Effects of Multisite Mutations in the Lipoic Acid Region of the BCOADC-E2 Protein. (2024/12/21) ♡
- Assessment of Non-alcoholic Fatty Liver Disease and Level of Risk of Fibrosis in Diabetic and Non-diabetic Individuals. (2024/12/21) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress. (2024/12/20) ♡
- Antiplatelet Prophylaxis Reduces the Risk of Early Hepatic Artery Thrombosis Following Liver Transplantation in High-Risk Patients. (2024/12/18) ♡
- Genetically predicted immune cells mediate the association between gut microbiota and autoimmune liver diseases. (2024/12/16) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Fibrillary Glomerulonephritis in a Patient With Sjögren's Syndrome and Primary Biliary Cholangitis: A Case Report and Literature Review. (2024/12/14) ♡
- The Differential Complement, Fc and Chemokine Receptor Expression of B Cells in IgG4-Related Pancreatobiliary Disease and Primary Sclerosising Cholangitis and Its Relevance for Targeting B Cell Pathways in Disease. (2024/12/13) ♡
- Transaneurysmal Suturing of Pseudoaneurysm Neck: Novel and Not a Pseudo-Technique for Treatment of Complicated Femoral Pseudoaneurysm. (2024/12/11) ♡
- Quantitative fibrosis identifies biliary tract involvement and is associated with outcomes in pediatric autoimmune liver disease. (2024/12/11) ♡
- Placental growth factor modulates endothelial NO production and exacerbates experimental hepatopulmonary syndrome. (2024/12/10) ♡
- Cytoskeleton Remodeling-Related Proteins Represent a Specific Salivary Signature in PSC Patients. (2024/12/07) ♡
- Mean liver density independently predicts therapeutic response and liver-related mortality in patients with primary biliary cholangitis. (2024/12/05) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Molecular Mechanisms of Fibrosis in Cholestatic Liver Diseases and Regenerative Medicine-Based Therapies. (2024/12/03) ♡
- Is an 8 mm cutoff necessary when performing primary common bile duct closure after laparoscopic common bile duct exploration? (2024/12/01) ♡
- Impact of Clinical Characteristics and Treatment on Cholangiocarcinoma Prognosis in Southern Thailand. (2024/12/01) ♡
- Percutaneous Transhepatic Cholangioscopy in Hepatolithiasis Associated With Decompensated Cirrhosis: A Retrospective Cohort Study. (2024/12/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Revisiting septic shock in cirrhosis: a call for personalized management. (2024/12/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Predicting and managing liver fibrosis in biliary atresia. (2024/12/01) ♡
- Disparities in Primary Biliary Cholangitis: A Retrospective Study Using Real-World Data From a Single Hepatology Clinic in the Greater Los Angeles Area. (2024/12/01) ♡
- Elafibranor Long-Term Efficacy and Safety and Impact on Fatigue in Primary Biliary Cholangitis: Interim Results From the Open-Label Extension of the ELATIVE Trial Up to 3 Years. (2024/12/01) ♡
- Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis and Compensated Cirrhosis in the Phase 3 Placebo-Controlled RESPONSE Trial. (2024/12/01) ♡
- Attenuation, Near Resolution, and Prevention of Pruritus in Patients With Primary Biliary Cholangitis Treated With Seladelpar: A Secondary Analysis of Patterns of Pruritus Change in the RESPONSE Trial. (2024/12/01) ♡
- The Effect of Obeticholic Acid on Inflammatory Markers and Fibrosis Scores in POISE Incomplete Responders: A Retrospective Review of POISE, a Phase 3 Trial of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis. (2024/12/01) ♡
- Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis: Pooled Interim Results for Up to 3 Years From the ASSURE Study. (2024/12/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Advances in the surgical technique of Kasai portoenterostomy. (2024/12/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Up-to-Date Snapshot of Current and Emerging Medical Therapies in Primary Biliary Cholangitis. (2024/11/30) ♡
- Performance of non-invasive fibrosis markers in biopsy-proven liver disorders. (2024/11/29) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Mouse Models for the Study of Liver Fibrosis Regression In Vivo and Ex Vivo. (2024/11/28) ♡
- Identification of the underlying molecular mechanisms of primary biliary cholangitis and ulcerative colitis comorbidity. (2024/11/26) ♡
- Diagnostic and Therapeutic Value of Endoscopic Retrograde Cholangiopancreatography in Acute Cholangitis: A Study From Kashmir Valley, India. (2024/11/25) ♡
- Development of a standardized monoclonal antibody to the inner lipoyl domain of PDC-E2 as a potential international AMA reference. (2024/11/23) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Modulation of gut microbiota by probiotics to improve the efficacy of immunotherapy in hepatocellular carcinoma. (2024/11/22) ♡
- Aramchol attenuates fibrosis in mouse models of biliary fibrosis and blocks the TGFβ-induced fibroinflammatory mediators in cholangiocytes. (2024/11/13) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Liver Failure in Autoimmune Hepatitis Overlap Syndrome With Primary Biliary Cholangitis: A Case Report. (2024/11/13) ♡
- Liver transcriptome analysis reveals PSC-attributed gene set associated with fibrosis progression. (2024/11/12) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Acute Viral Hepatitis E Presenting With Bell's Palsy and Acute Pancreatitis: A Case Report. (2024/11/07) ♡
- Risk of hepatocellular carcinoma in Asian patients with primary biliary cholangitis: A nationwide and hospital cohort study. (2024/11/06) ♡
- Dissecting the genetic basis and mechanisms underlying the associations between multiple extrahepatic factors and autoimmune liver diseases. (2024/11/05) ♡
- Branched-chain amino acids and their metabolites decrease human and rat hepatic stellate cell activation. (2024/11/04) ♡
- Oral N-acetylcysteine ameliorates liver fibrosis and enhances regenerative responses in Mdr2 knockout mice. (2024/11/03) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study. (2024/11/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium. (2024/11/01) ♡
- Comparison of target concentration of propofol during three phases of live donor liver transplant surgery using a target-controlled infusion of propofol total intravenous anaesthesia - A prospective, observational pilot study. (2024/11/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The Difficulties of Treating Complement-3-Mediated Glomerulopathy. (2024/11/01) ♡
- Management of Suboptimal Response in Primary Biliary Cholangitis Treatment. (2024/11/01) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.